Abstract:Background: The 2007 European Union (EU) regulation on medicinal products for pediatric use may change the present unsatisfying situation in the EU by stimulating research and development of medicines for use in children through rewards and incentives. Objectives: This commentary reflects on the new EU regulations and guidelines, with special attention paid to the impact on pediatric formulation science. The focus of this article is on the EU perspective for pediatric formulations and highlights the differences compared with the pediatric drug formulation situation in the United States. Methods: Materials for this article were gathered during a literature search of MEDLINE and Chemical Abstracts (1970-October 2008) using the following terms: paediatric/pediatric drug formulations, age-appropriate dosage forms, child-appropriate medicines, and paediatric/pediatric regulation. Results: Since the EU legislation on medicines for children came into force in 2007, a great emphasis has been placed on creating new organizations, scientific networks, and programs dealing with pediatric medicines and child-appropriate drug formulations. Although the US legislation was an appropriate model, the EU introduced some novel measures to improve the current situation, such as the Paediatric Investigation Plan and the Paediatric Use Marketing Authorisation. For globally operating pharmaceutical companies, the peculiarities of the European market have a strong impact on their product development strategies. Because the European approach demands early investigations into drug formulations for children, various issues must be resolved, including the following: choosing formulations for each age group, determining which excipients may be used in the formulation and which delivery device is appropriate, and predicting the taste sensation of an oral formulation. Numerous initiatives and networks are evolving in Europe. An important future task will be the coordination of these activities and the linking to other groups working on pediatric formulations outside the EU. Conclusion: Similar to the research in pediatric drug formulations that was stimulated by the US legislation and incentives of the last decade, the 2007 EU legislation promises improvements in the availability of child-appropriate drugs in Europe.

Selecting appropriate excipients for paediatric dosage form - Paediatric excipients risk assessment (PERA) framework - Part 1

Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units

Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives

Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements

Development of Paediatric Medicines: Key Risk Factors and Non-clinical Research Programmes

Paediatric Drug Development and Formulation Design—a European Perspective

Paediatric formulations—part of the repurposing concept?

Extent of Safety Database in Pediatric Drug Development: Types of Assessment, Analytical Precision, and Pathway for Extrapolation through On-Target Effects

How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges

European perspectives on pediatric formulations

Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics.

Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study

General Clinical and Methodological Considerations on the Extrapolation of Pharmacokinetics and Optimization of Study Protocols for Small Molecules and Monoclonal Antibodies in Children

The challenge of downstream processing of spray dried amorphous solid dispersions into minitablets designed for the paediatric population – A sustainable product development approach

Pediatric Drug Development Process: A Review

Challenges in the assessment of adverse drug reactions in children and neonates

Formulation Challenges and Strategies to Develop Pediatric Dosage Forms

Paediatric medicine issues and gaps from healthcare workers point of view: survey results and a narrative review from the global accelerator for paediatric formulations project

USFDA-approved parenteral peptide formulations and excipients: Industrial perspective

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: a quality improvement report